Enanta Pharmaceuticals Inc (ENTA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $310.77M
Last updated: Nov 17, 2026 at 4:20 PM ET
Enanta Pharmaceuticals Inc (ENTA) Statistics
Enanta Pharmaceuticals (ENTA) has a market cap of $310.77M and an enterprise value of $277.35M. Its share count is up 36.08% from a year earlier. It kept -96.89% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 10.75% below the market cap, as cash exceeds debt.
| Market Cap | $310.77M |
|---|---|
| Enterprise Value | $277.35M |
| Latest price (Nov 17, 2026) | $8.69 |
Key Dates
The next earnings report is expected on Feb 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 16, 2026 |
| Fiscal Year End | September |
Valuation Ratios
Sales and book value multiples are 3.9x and 2.5x. Its year-end P/S ranged from 1.8x to 16.3x from 2016 to 2025.
| P/S Ratio | 3.9x |
|---|---|
| Forward P/S | 4.9x |
| P/B Ratio | 2.5x |
Price Statistics
The stock is down 27.94% over 52 weeks and trades 26.23% below its 50-day average.
| Beta (1Y) | 1.10 |
|---|---|
| 52-Week Change | -27.94% |
| 1-Month Change | -23.84% |
| 3-Month Change | -35.68% |
| 6-Month Change | -36.85% |
| 5-Year Change | -87.52% |
| 10-Year Change | -54.46% |
| Total Return (1Y) | -27.94% |
| Total Return (3Y CAGR) | -1.63% |
| Total Return (5Y CAGR) | -37.72% |
| Return vs SPY (1Y) | -41.25% |
| Max Drawdown (1Y) | -48.43% |
| Max Drawdown (3Y) | -75.60% |
| Sharpe Ratio (1Y) | -0.67 |
| Correlation with SPY (1Y) | 0.29 |
| 50-Day Average | $11.78 |
| 200-Day Average | $13.06 |
| 52-Week Range | $10.05 to $17.15 |
| RSI (14 Days) | 29.9 |
| Average Volume (20 Days) | 293.20K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.76x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 3.76x |
|---|---|
| Quick Ratio | 3.76x |
| Debt / Equity | 0.00x |
| Interest Coverage | -4.54x |
Returns and Efficiency
Return on equity is -62.56% over the last 12 months, against a 5-year average of -67.21%.
| Return on Equity (ROE) | -62.56% |
|---|---|
| Return on Assets (ROA) | -21.30% |
| Return on Capital Employed (ROCE) | -23.33% |
| ROE (5Y Average) | -67.21% |
| ROA (5Y Average) | -27.87% |
| ROIC (5Y Average) | -68.81% |
| Asset Turnover | 0.22x |
| Receivables Turnover | 9.10x |
Scores
ENTA has an Altman Z-Score of -1.17, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -1.17 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $65.26M over the last 12 months is up 0.70% from the 12 months before.
| Revenue | $65.26M |
|---|---|
| Revenue Growth (YoY) | +0.70% |
| Gross Profit | $65.26M |
| Operating Income | -$58.73M |
| Pretax Income | -$63.13M |
| Net Income | -$63.23M |
| EBITDA | -$51.38M |
| EBIT | -$56.62M |
| Reported EPS (TTM) | -$2.35 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 34.05% of the $296.87M in total assets.
| Cash and Equivalents | $33.42M |
|---|---|
| Total Debt | $0 |
| Net Cash | $33.42M |
| Net Cash Per Share | $1.15 |
| Working Capital | $149.45M |
| Shareholder Equity | $101.07M |
| Book Value Per Share | $3.47 |
| Total Assets | $296.87M |
| Total Liabilities | $195.80M |
Balance sheet as of Jun 30, 2026.
Cash Flow
After $1.62M of capital spending, operating cash flow left -$36.94M of free cash flow.
| Operating Cash Flow | -$35.32M |
|---|---|
| Capital Expenditures | $1.62M |
| Free Cash Flow | -$36.94M |
| FCF Per Share | -$1.27 |
| Depreciation and Amortization | $6.20M |
Trailing 12 months through Jun 30, 2026.
Margins
The operating margin is -89.99%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -89.99% |
| Pretax Margin | -96.74% |
| Net Margin | -96.89% |
| EBITDA Margin | -78.74% |
| EBIT Margin | -86.77% |
| FCF Margin | -56.60% |
Growth
Revenue fell 8.82% a year over 3 years.
| Revenue Growth (3Y CAGR) | -8.82% |
|---|---|
| Revenue Growth (5Y CAGR) | -11.81% |
| Book Value Per Share Growth (2Y CAGR) | -45.77% |
| Tangible Book Per Share Growth (2Y CAGR) | -45.77% |
Dividends and Yields
ENTA does not pay a dividend. Its free cash flow yield is -14.61%.
| FCF Yield | -14.61% |
|---|---|
| Buyback Yield | -27.67% |
| Shareholder Yield | -27.67% |
Peer Position
Against 7 similar companies, ENTA has the 6th highest P/S.
P/S RatioPeer median 7.4x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -68.74%
| P/S Ratio | 3.9x vs 7.4x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +0.70% vs -68.74% median |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ENTA
What is ENTA's market cap?
Enanta Pharmaceuticals has a market cap of $310.77M. Its enterprise value, which adds debt and subtracts cash, is $277.35M.
How many shares of ENTA are outstanding?
Enanta Pharmaceuticals has 29.09M shares outstanding. The count is up 36.08% from a year earlier.
Does ENTA pay a dividend?
No. Enanta Pharmaceuticals does not pay a dividend.
How much debt does ENTA have?
Enanta Pharmaceuticals has $0 of total debt and $33.42M of cash and equivalents, a net cash position of $33.42M.
ENTA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors